- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Ecchymosis.
Displaying page 1 of 2.
EudraCT Number: 2005-002101-23 | Sponsor Protocol Number: 25-03-05 Version 4 | Start Date*: 2006-02-28 |
Sponsor Name:North West London Hospitals NHS Trust, R&D Office | ||
Full Title: Do Steroids Provide Additional Benefit Over Pressure Alone In Reducing Oedema And Ecchymosis Following Rhinoplasty? A Randomised, Prospective, Double Blind, Placebo Controlled Clinical Trial | ||
Medical condition: Nasal deformity requiring corrective surgery i.e Rhinoplasty | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021270-11 | Sponsor Protocol Number: CL2-05682-102 | Start Date*: 2010-09-30 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in patients operated on for varicose veins with conservation of the great saphenous vein. A multicentre, double bl... | |||||||||||||
Medical condition: Patients suffering from chronic venous disease and for whom ASVAL (Ambulatory Selective Varicose veins Ablation Local anesthesia) surgery is indicated. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002118-37 | Sponsor Protocol Number: HTAJ-TRANEX-2019-01 | Start Date*: 2021-06-17 |
Sponsor Name:Rafael Blancas-Gómez Casero | ||
Full Title: MULTICENTER, DOUBLE BLIND CLINICAL TRIAL TO EVALUATE THE ANTIHEMORRAGIC EFFECT OF THE TOPICAL TRANEXAMIC ACID DURING PACEMAKER IN ANTICOAGULATED PATIENTS | ||
Medical condition: Pacemaker implant for anticoagulated patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000734-35 | Sponsor Protocol Number: TV48125-CNS-10141 | Start Date*: 2019-07-25 |
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
Full Title: A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous administration of Fremanezumab in Pediatric Migraine Patients (6 to 11 Years of Age ... | ||
Medical condition: Prevention of migraine | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-001404-20 | Sponsor Protocol Number: V58P1S | Start Date*: 2007-05-14 |
Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG | ||
Full Title: A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of a single intramuscular dose of a trivalent subunit influenza vaccine produced in mammalian cell cul... | ||
Medical condition: No medical condition; healthy volunteers will be recruited into clinical trial for annual approval of Influenza vaccine with new strain composition according to WHO and EMEA recommendation and CPMP... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001403-38 | Sponsor Protocol Number: V44P11S | Start Date*: 2007-05-10 |
Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG | ||
Full Title: A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 200... | ||
Medical condition: No medical condition, healthy volunteers will be recruited into clinical trial for annual approval of influenza vaccine with the new strain composition according WHO and EMEA recommendation and CPM... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005243-25 | Sponsor Protocol Number: GID37 | Start Date*: 2013-04-16 | |||||||||||
Sponsor Name:Sanofi Pasteur | |||||||||||||
Full Title: Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route) | |||||||||||||
Medical condition: Prophylaxis of influenza (2013-2014 Northern Hemisphere Season) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000438-11 | Sponsor Protocol Number: V44P10S | Start Date*: 2006-05-05 |
Sponsor Name:Chiron Behring GmbH & Co KG | ||
Full Title: A Phase III, Multicenter, Uncontrolled, Open-label study to evaluate Safety and Immunogenicity of Begrivac, preservative free inactivated Split Influenza Vaccine, using the Strain Composition 2006/... | ||
Medical condition: no medical condition; healthy volunteers will be recruited into clinical trial for annual approval of Influenza vaccine with new strain composition according to WHO and EMEA recommendation and CPMP... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001044-35 | Sponsor Protocol Number: GQM00016 | Start Date*: 2019-02-08 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 months to 17 Years | ||
Medical condition: Prophylaxis of influenza (Northern Hemisphere 2017-2018 season) in children aged 6 months to 17 years | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-017688-40 | Sponsor Protocol Number: GID34 | Start Date*: 2010-04-16 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route) | ||
Medical condition: Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intraderma route | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-009977-85 | Sponsor Protocol Number: GID29 | Start Date*: 2009-05-19 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route) | ||
Medical condition: Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intradermal route | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017690-38 | Sponsor Protocol Number: GRT90 | Start Date*: 2010-04-06 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route) | ||
Medical condition: Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000430-20 | Sponsor Protocol Number: V44P9S | Start Date*: 2005-06-02 |
Sponsor Name:Chiron Behring GmbH & Co KG | ||
Full Title: A phase III, multicenter, uncontrolled, open label study to demonstrate safety, tolerability and immunogenicity of the Chiron Behring preservative free inactivated split influenza vaccine using the... | ||
Medical condition: no medical condition; healthy volunteers will be recruited into clinical trial for annual approval of Influenza vaccine with new strain composition according to WHO and EMEA recommendation and CPMP... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000887-18 | Sponsor Protocol Number: V44P12S | Start Date*: 2008-05-13 |
Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co KG | ||
Full Title: A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 200... | ||
Medical condition: No medical condition, healthy volunteers will be recruited into clinical trial for annual approval of influenza vaccine with the new strain composition accordng WHO and EMEA recommendation and CPMP... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000285-38 | Sponsor Protocol Number: APHP190020 | Start Date*: 2019-08-21 |
Sponsor Name:London School of Hygiene and Tropical Medicine | ||
Full Title: Pharmacokinetics of Tranexamic Acid after oral, intramuscular or intravenous administration: a prospective, randomised, cross-over trial in healthy volunteers. | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017781-23 | Sponsor Protocol Number: 720903 | Start Date*: 2010-01-18 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population | |||||||||||||
Medical condition: To verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season, manufactured according to the ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019835-37 | Sponsor Protocol Number: GPF15 | Start Date*: 2010-06-29 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects | ||
Medical condition: Preventive vaccination study in healthy subjects aged 18-60 years and over 60 years against infection with H5N1 Influenza Virus A/Indonesia/5/05-RG2 (H5N1) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) FR (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-003172-43 | Sponsor Protocol Number: TV48125-CNS-30058 | Start Date*: 2017-05-31 |
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
Full Title: A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache | ||
Medical condition: Cluster headache (CH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Completed) PL (Prematurely Ended) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003603-37 | Sponsor Protocol Number: V87_25 | Start Date*: 2014-02-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderl... | |||||||||||||
Medical condition: Pandemic Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005558-63 | Sponsor Protocol Number: V70P3 | Start Date*: 2006-11-28 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | |||||||||||||
Full Title: A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nona... | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
